Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Keywords
unspecified adult solid tumor, protocol specific
Brief summary
RATIONALE: Drugs used in chemotherapy, such as methoxyamine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of methoxyamine when given together with temozolomide in treating patients with advanced solid tumors.
Detailed description
OBJECTIVES: * To determine the maximum tolerated dose of methoxyamine given in conjunction with temozolomide in patients with and without CNS disease. * To determine the dose limiting toxicities of the combination of methoxyamine and temozolomide in patients with and without CNS disease. * To determine the pharmacokinetics of these two agents when given alone or in combination, as well as the pharmacokinetic profile of methoxyamine after single one-hour IV administration. * To determine relative DNA damage, as single or double strand breaks by comet assay in blood mononuclear cells which will serve as a surrogate for tumor response to the drug combination. OUTLINE: This is a dose escalation study of methoxyamine. Patients receive oral temozolomide for 5 days every 28 days and methoxyamine IV over 1 hour every 28 days. Methoxyamine IV administration will follow, within 5 minutes, initial administration of TMZ on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for correlative studies. Samples are analyzed for methoxyamine and temozolomide pharmacokinetics, apurinic/apyrimidinic sites, and DNA strand break determination by comet assay.
Interventions
DRUGMethoxyamine
For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
DRUGTemozolomide
Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Sponsors
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a histologically confirmed solid tumor that is considered incurable and is not amenable to conventional surgical, radiation therapy or chemotherapy treatment programs. * Prior chemotherapy and/or radiation are allowed. At least 3 weeks must have elapsed since prior large-field radiation therapy; patients must have been off previous anti-cancer therapy for at least 3 weeks (6 weeks for mitomycin-C and nitrosoureas); and recovered from all treatment related toxicity to \< grade 1 according to NCI CTCAE version 3.0 (with the exception of alopecia and radiation-induced taste changes). Prior temozolomide treatment is not restricted. * ECOG performance status (PS) 0-2 (Karnofsky PS 50-100%) * Life expectancy ≥ 12 weeks * Patients must have normal organ and marrow function as defined below: * Absolute neutrophil count ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Hemoglobin ≥ 10.0 g/dL * Total bilirubin ≤ 1.5 mg/dL * AST ≤ 2.5 times upper limit of normal * Creatinine ≤ 1.5 mg/dL and/or creatinine clearance ≥ 60 mL/min * Patients with known primary or metastatic CNS disease, are eligible for participation in cohort B, but not in cohort A. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Patients may not be receiving any other investigational agents or have received other investigational agents for at least 3 weeks. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant and lactating women are excluded from this study because the methoxyamine and temozolomide combination is likely to be teratogenic. * NYHA classification III or IV heart disease * Patients with known primary or metastatic CNS disease (cohort B) are not eligible if they have a mini mental status exam score \< 15 or evidence of leptomeningeal disease. * Patients with pre-existing neurologic toxicity \> grade1 (as per CTCAE, version 3.0) are not eligible for participation in cohort A. * Patients screened for participation in cohort B with pre-existing neurologic toxicity \> grade 2 (as per CTCAE, version 3.0) are not eligible, unless pre-existing neurologic toxicity is documented in detail and patient's participation in the trial has been approved by the neuro-oncology team at participating institutions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose of methoxyamine | Courses repeat every 28 days in the absence of unacceptable toxicity. | A total of 38 patients were analyzed to determine the maximum tolerated dose of methoxyamine in this study and this was determined in the non-CNS arm. An initial 6 patients received treatment with continuous dosing of methoxyamine and based on an assessment of pharmacokinetics, in this group, the study was revised to administer methoxyamine as a bolus dose. Thirty-eight patients received this type of dosing. |
| Dose limiting toxicities of the combination of methoxyamine and temozolomide | Courses repeat every 28 days in the absence of unacceptable toxicity. | The 38 patients receiving bolus dosing of methoxyamine in this trial were used to determine any dose limiting toxicities. |
| Pharmacokinetics methoxyamine and temozolomide, when given alone or in combination | Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. | Thirty-eight patients were analyzed per the schedule above (after an initial 6 patients treated per an alternative dosing schedule). |
Countries
United States
Outcome results
None listed